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The Quest for an

AIDS Vaccine

Robert

T

Schooley, M.D.

More than fifty thousand cases ofAIDS have been reported in the United States since the
disease was first described in 1981. Many times this number ofpeople are infected with
human immunodeficiency virus (HIV), which has been identified as the agent responsible
illness. The seriousness of the disease, coupled with the relatively rapid spread of
HIV, has fueled the effort for development of an effective vaccine.

for the

Much is now known about the life cycle of the virus, and about its structural compoand information about methods of transmission of the virus, form
a rational vaccine development program. A successful program depends both
on technological advances and on the political will to create a climate in which interpret-

nents. This information,

the basis for

able vaccine trials can be undertaken. This review will focus on some of the impediments
to rapid

development and licensure of an AIDS vaccine.

Since the initial description of AIDS in 1981

,

and the

initial definition

of the

human

immunodeficiency virus (HIV) as the etiologic agent for the syndrome, much progress has

been made in understanding the

ing the components of the

cell

and molecular biology of HIV, and in definIn parallel with the growth in

immune response to the agent.

basic understanding of HIV, the agent has spread rapidly in the United States and world-

wide, primarily through sexual, blood-borne, and perinatal exposure.

mated

that

between

1

It

has been

esti-

million and 3 million residents of the United States are currently

infected with HIV, and that at least as

many

individuals are infected in other parts of the

world. This relatively rapid spread of HIV, despite educational efforts aimed at interdicting spread of the agent, underscores the urgent

AIDS vaccine.

need for development of an effective

This article will outline current prospects for development of an

AIDS

vaccine, and will delineate the steps required for the proof of efficacy in clinical trials.

Initial Infection

HIV

and Spread of HIV

gains access to the

Dr. Robert

T.

Schooley

is

body

either transmucosally (across

mucous membranes)

associate professor of medicine at the Harvard Medical School

Infectious Disease Unit at the Massachusetts General Hospital.
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transmission, or directly into the bloodstream or soft tissues with blood-borne (needle
stick or transfusion) exposures (figure 1). In that the virus lives primarily within cells,

Once
The genetic material of the virus is
acted upon by an enzyme known as reverse transcriptase, which is brought into the cell by
the virus. The genetic material of the virus is then integrated into the host cell DNA. The
it is

not clear whether spread involves free virus or virus transmitted within cells.

within the

new

host, the virus enters susceptible cells.

may remain latent and be transmitted to any progeny of the infected host cell, or it
may begin to reproduce and be transmitted to previously uninfected, susceptible cells.
virus

Although

it is

possible that a vaccine might slow secondary transmission of virus to unin-

fected cells, the primary goal in

lishment of the

most vaccination programs involves prevention of estab-

initial infection.

In the case of HIV, this

initial

interception of virus by the

immune response might be

complicated by the ability of the virus to spread directly from infected to uninfected lymphocytes through cell-to-cell spread, and by the possibility that the
cells

might occur

at

mucosal surfaces such as vaginal and

initial infection

of host

rectal linings. Initial infection at

these sites might significantly limit the effectiveness of immune response induced by
traditional vaccines.

Figure 1
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The figure describes interaction between HIV and the infected individual. The virus gains entry to the
body through mucous membranes with sexual exposure, or more directly through blood-borne
exposure. After entry, the virus infects certain cells of the immune system and the brain. The immune
response that is evoked by the virus is multifaceted and probably slows the rate at which the virus
causes illness. Greater knowledge about the characteristics of this immune response will be useful
vaccine development.
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in

,

Host

Immune Response to HIV

Once the

virus

is

within an individual, replication of HIV proceeds at a rate that

dependent on a number of factors, including the
specific host
initial

immune response;
is

developed.

As the
immune re-

and, possibly, virus-specific strain differences.

The antibody response to HIV

components. These antibodies are useful diagnostically

infected individuals, but,

may be

of activation of host cells; the HIV-

cycles of viral replication proceed, a vigorous antibody and cellular

sponse to the virus
viral

state

more important,

is

directed to a

number of

in the identification of

HIV-

they provide insight into the components of the

virus recognized by the host as being foreign.

Antibody

activity

the antibodies.

The

of vaccine strategy
are

can be measured in functional assays that measure biologic effects of
functional assay that has been

is

most extensively studied

for the

purpose

the neutralization assay. In this assay, dilutions of sera to be tested

mixed with a known amount of virus. After exposure of the virus

to

serum

for a de-

fined length of time, the ability of the serum-exposed virus to infect susceptible cells
tested. If protection of susceptible cells

serum

is

by a given dilution of serum

is

is

demonstrated, the

said to contain neutralizing activity at that dilution. Neutralizing activity appears

within the serum of most HIV-infected individuals within the first several months following infection. These assays are useful in planning vaccine approaches because they permit
investigators to determine
its ability

which parts of the virus are able

to infect host cells. In the case of

HIV-1

the United States), this neutralizing activity

is

(the

most

to elicit antibodies that cripple

most

common AIDS virus type in

easily demonstrated in antibodies that

react with the envelope (surface) of the virus.

Although one can demonstrate neutralizing
such knowledge

is

far

from

such antibodies must be present at the

mucosa. Furthermore,

activity specific for the envelope of HIV-1

sufficient for providing an effective vaccine.
site

As noted

above,

of initial infection, such as the rectal or vaginal

HIV possesses an envelope that varies

significantly

from

strain to

strain. In addition to the

two currently known types of HIV, within each type there are

many, many

may be
may be incapable of doing so. In addition,
second type of HIV, now termed HIV-2, which was initially iso-

strains.

Thus, an antibody that

is

able to neutralize one strain of virus

less able to neutralize other strains of virus, or

with the description of a

lated in west Africa, vaccine

development

is

faced with the need to deal with at least two

types of HIV

Although the antibody response
been most intensively studied,

to

HIV is the aspect of the immune response which has

one
component of a multifaceted response. In addition to antibodies that neutralize the virus,
cytotoxic (killer) T-cells are induced by HIV infection. These cells are capable of seeking
out and killing HIV-infected cells. They, thus, form a second impediment to uncontrolled
replication of the virus, and may play an important role in slowing the rate at which HIV
causes symptoms in infected individuals. These cytotoxic T-cells are directed at the envelope of HIV, but, in addition, cells with activity against other components of HIV are
present. The other components of HIV tend to vary less from strain to strain and thus are
more conserved. These observations are of importance in AIDS vaccine development in
that inclusion of more strictly conserved components might allow development of vacit is

clear that neutralizing antibodies represent only

cines that have activity against a wider variety of strains.

Because of the relentless progress of infection
the HIV-specific

in

most individuals, the effectiveness of

immune response that can be detected within the first

infection has been called into question. Despite this consideration,
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months of

should be noted that
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individuals, once infected with

one

strain of virus, are rarely, if ever, infected

by other

even when repeated exposure to other strains occurs frequently. This suggests that

strains,

although the naturally occurring
following infection,
virus. Thus, if an

it is

at least

immune response might

immune response that closely mimics

infection can be elicited by an

fail to

prevent onset of disease

capable of preventing infection with additional strains of

AIDS

the response following natural

vaccine, subsequent infection with live virus might

well be preventable.

Steps in the Development of an

As basic understanding

AIDS Vaccine

of the HIV-specific

immune response is

developed, application

of this information to the technical aspects of vaccine development will be increasingly

immune response requires delivery of an appropriate
immune system prior to exposure to the natural agent.

effective. Induction of an effective

stimulus (termed antigen) to the

Antigen delivery may be achieved through the use of either living or nonliving material
(table 1).

One of the oldest approaches to vaccines has involved growing the agent itself in

the laboratory, then purifying and killing
rial is

by chemical means. The purified, killed mate-

it

then injected into the individual being vaccinated and, thus,

immune
vaccine

response.

is

The magnitude of the immune response

delivered (that

is,

whether

it is

is

is

presented to the

highly dependent on

injected or given by other routes) and

or other materials (termed adjuvants) that

may be added to the killed virus.

how

a

on carrier

Killed virus

approaches have the advantage that they are technologically straightforward, but the disadvantage that most of the material injected consists of portions of the infectious agent that
are irrelevant to the

immune response in developing protective immunity. Thus, the theoundesired vaccine side effects may be induced by the pres-

retical possibility exists that

ence of unnecessary vaccine components. Finally, there
inactivation procedure

may be incomplete.

is

the unlikely possibility that the

do not comwhich the vaccine is intended in the first
least one instance in which killed vaccine

If the vaccine preparation steps

pletely kill the virus, infection with the agent for

place could occur. In addition, there has been at

was contaminated with a virus of a different type (in the case of an early lot of polio vaccine) which was not killed by the inactivation procedure. Although these two latter possibilities

are increasingly unlikely with

modern technology,

they are not totally outside the

realm of possibility.

Table 1

Antigen Delivery Systems
A. Nonliving antigen delivery

B.

1.

Killed

2.

Viral

whole

systems

virus

components
from whole virus

a.

Purified

b.

Prepared by recombinant

Live antigen delivery
1.

Attenuated virus

2.

Viral

components

DNA technology

systems

carried

by

a

nonpathogenic

unrelated virus
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(or

minimally pathogenic)

A second approach to vaccine preparation using nonliving material involves use of viral
components, termed subunits. These subunits can be purified from whole, killed virus,
or they can be prepared with

DNA technology.

This approach involves introduction of a

selected portion of the viral genetic information into the genetic material of another living

organism, such as a bacterium or a yeast. The material normally encoded by the viral

gene selected

is

then

large amounts of the

and

fied

made by the new host. When the new host is grown in the laboratory,
HIV component are also produced. This material can then be puri-

utilized as a vaccine.

The advantage of this approach

produce well-characterized portions of the virus

is

at great purity.

that

By

it

has the potential to

selecting a portion of

the viral genetic material which encodes for portions of the virus which appear to be targets of the protective component(s) of the

immune response, one can avoid introduction of

deleterious or irrelevant viral components. Thus, one could include only selected portions

of the viral envelope or other components. Recombinant
vantage, however, of producing material that might be

response that

is

to induce

specific only for the strain (or closely related strains)

genetic information was procured. Recombinant

initial

DNA technology has the disad-

more likely

an immune

from which the

DNA technology also runs the risk

of producing material that will be slightly different from the material encoded by the
native gene,

owing

These events
and

relate

to events that occur within cells following initial protein production.

mainly to the way in which the proteins are folded after production,

to the addition of sugar molecules.

circumvented some, but not

all,

Newer developments

in molecular biology have

of these problems.

Live virus approaches have several potential advantages over those utilizing nonliving
material.

These include the

fact that vaccine delivery

example, through oral or aerosol routes).

(for

proaches

may be more likely to

stimulate a

It

may be achieved without injection

has also been said that live agent ap-

more global immune

response, both in terms

of the viral components recognized and in terms of the development of immunity at likely
sites

of infection, such as mucosal surfaces.

The live virus approach that is used most

frequently involves the introduction of changes (termed attenuation markers) in the nor-

mal

viral genetic material

which make the agent

less likely to

has been modified by addition of these attenuation markers

is

cause disease.

A virus that

termed an attenuated

virus.

immune response developed during

Once the host has

dealt with the attenuated virus, the

this interaction is

capable of preventing infection with the natural (wild) virus. This ap-

proach

The

is

the one that

was used

nated contacts of the persons

initially vaccinated.

lead to the protection of others,

may be good
agent

in the production of the Sabin vaccine for polio.

final potential advantage of live agent vaccines is that they

is

might spread

to unvacci-

Thus, vaccinating one individual might

who become secondary vaccinees. Secondary vaccination
harm exists, as well, if the attenuated
immune responses are incapable of preventing
strain of virus used in the vaccination. The biggest

for the population, but the potential for

introduced into individuals whose

morbidity even from the attenuated

drawback concerning the use of attenuated viruses as vaccines relates to uncertainty as
to whether the changes introduced to include attenuation are stable. If these attenuation
markers revert to the wild state after replication begins to occur in an individual receiving
the vaccine, the deleterious effects are obvious.

An alternative to using attenuated virus involves the insertion of a portion of the viral
genetic material important for induction of immunity into an agent that does not normally

cause

illness.

As

the agent of low pathogenicity replicates, the host

immune response is

also presented with the immunologically relevant portion(s) of the agent being vaccinated
against.

The

resulting

immune response then,

in theory, prevents infection with the wild

139
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agent

if

it is

many of the advan-

subsequently encountered. Although this approach shares

tages of the attenuated virus approach, the possibility of inadvertently introducing wild

virus

is

eliminated.

One of the potential

hazards, however, relates to concerns that while

the carrier virus chosen might be unable to cause disease in individuals with intact im-

mune responses,

it

might be capable of causing severe disease

in individuals

with

immune

dysfunction. In the case of the most intensively studied carrier virus (vaccinia), such con-

cerns would exist in vaccination plans in which individuals
fected might be inadvertently vaccinated. This concern

who were already

would include

HIV-in-

either direct or

secondary vaccination, as discussed above.

Current Status of HIV Vaccine Research
At the time of this writing (March 1988), a large number of academic and industrial investigators have focused attention on AIDS vaccine research and production. Most of the
scientific attention has centered

on approaches

that utilize the viral envelope or portions

of the envelope as the primary component of candidate vaccines. Live and killed virus

approaches have succeeded in producing immunogenes (vaccines) that induce neutralizing
antibodies in laboratory animals ranging
if

not

all,

to

nonhuman primates. To date, most,

from which the candidate vaccine was derived. Thus, attempts

strain or type of the virus
to

from mice

of the animals vaccinated have produced antibodies that will neutralize only the

produce a vaccine

that

might offer broad protection against a wide variety of strains or

types have been unsuccessful. Vaccines useful in the United States
in parts of the

may have limited utility

world where other viral strains are prevalent.

Only a handful of studies have progressed

to the point that

chimpanzees have been vac-

cinated with a candidate vaccine and then have been challenged with live virus.

Most of

these studies have not yet been reported in peer-reviewed scientific literature. In these
studies, in general, although neutralizing antibodies have

been

elicited

by the candidate

vaccines, animals subsequently inoculated with live virus, even of the vaccine strains,

have become infected. This failure to prevent infection might stem from any one of a

number of factors. These include

the inadequacy of the candidate vaccine and the proba-

bility that the live virus inoculation studies

chimpanzee challenge studies performed
nously with

many thousands

have used an excess amount of virus. In the

to date,

most animals are challenged

of infectious virions. In

human

infection,

it is

intrave-

clear that

most

sexual exposures do not result in transmission of virus. Those exposures which result in
infection

may do

so because slightly

rectal or vaginal surfaces.

reflect

human

infection,

inoculated with

much

it

more

virus

is

present, or because of defects in the

Thus, in order for the chimpanzee challenges to accurately

would be necessary

to

develop a model whereby animals were

smaller amounts of virus, preferably administered to mucosal sur-

most animals would not become infected. In order to demonwould be necessary to vaccinate a large number of chimpanzees, and
then inoculate them with a small enough amount of virus that most of them would not

faces. In such inoculations,
strate protection,

to

become
with a

it

infected, even if unvaccinated. In such a study,

test

vaccine and another 100 with a

sham

one might immunize 100 animals

(or fake) vaccine.

One would then

inocu-

each animal with an amount of virus just in excess of what might infect a minority of
unvaccinated animals. At the end of a study like this, a successful vaccine might reduce
late

the

number of infected animals from

8 of the 100 in the sham-vaccinated group to 2 of the

100 in the group receiving the active vaccine. Such studies would require tens to hundreds
of chimpanzees per vaccine candidate. Given the short supply of chimpanzees, and the

140

cost of each animal (currently approximately $70,000),

it is

unlikely that such studies are

feasible.

Thus,

at this point, a

number of vaccine candidates have been developed. Many produce

None has

neutralizing antibodies in vaccinated animals.

animals from live virus challenge. Even
tion in the
real

world

setting.

yet

been demonstrated

a vaccine demonstrated protection

to protect

from

infec-

would not necessarily imply protection of humans in the
Therefore, even with all the knowledge theoretically available from

chimpanzee model,

animal studies,

if

human vaccine

it

studies will be required prior to licensure of an

AIDS

vaccine.

Human Studies with Candidate AIDS Vaccines
The human
will

studies that

must be undertaken

in the evaluation process for

be patterned after such studies with other vaccines

from simple dose-finding

studies progressing

AIDS vaccines

A logical sequence of

in the past.

studies to larger-scale clinical trials will

assure the most timely evolution of AIDS vaccine and will minimize the inherent risks to
study subjects which are encountered with evaluation of any vaccine or drug product.

The process
vaccine

is

that is generally followed involves

Phase

administered to a small group of healthy

I

studies, in

which the candidate

human volunteers who are at minimal

risk for acquiring the agent being vaccinated against. In these studies, the

primary goal

is

to

determine whether any toxicities not anticipated from animal studies might be manifest

in

human

subjects. In addition, through the use of several laboratory assays, these studies

seek to measure the magnitude of the

immune response induced by

the vaccine. This en-

deavor will not necessarily identify adverse effects that might occur
that

might occur

at a

in populations not included in the preliminary testing.

changes that are measured will be useful only in that they will indicate
nologic impact of the vaccine in

humans

is

low frequency or

The immunologic
whether the immu-

similar to that experienced by animals in the

prior studies.

The Phase

I

studies

vaccine, and might
is

might involve several different vaccination schedules or doses of

compare

when the vaccine
some vaccine develop-

the magnitude of the response encountered

given with various adjuvants (immune-enhancing materials). In

ment programs, the Phase I studies are performed in several stages, in which adverse
and immunologic effects are measured in a very small group of volunteers (five to ten
persons) before they are repeated or modified for application to a larger number of
volunteers.

After Phase

I

been completed, information should be

testing has

in

hand about optimal

dosing schedules and adverse effects of a vaccine. The next phase of the studies focuses on

whether a vaccine actually prevents infection

group or groups

at risk for

placebo-controlled
three groups

trial.

in the field. In

such studies, members of a

acquiring the agent are recruited and invited to participate in a

In these studies, subjects are randomly allotted to one of two or

who will either receive the vaccine candidate or an identical-appearing pla-

cebo. Subjects are allotted by chance to these groups; neither the subject nor the investigator

knows who receives the

theoretically active material. Subjects are then followed to

determine whether the group or groups receiving the vaccine are infected
over time than those

who

receive the placebo. Only after such evidence

vaccine considered safe and effective and

is it

is

at a

in

lower rate

hand

is

a

offered for general use. Such information

is

mandatory, because premature licensure and use of an ineffective vaccine would give the
public a false sense of security and would encourage behavior that would increase the rate
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of infection. In general, most effective vaccines offer a significant degree of protection,
but not complete protection.
ness of a vaccine

is

The speed with which

directly related to the rate at

a

trial

can demonstrate the effective-

which the study population acquires the

who are protected

agent being studied, and to the proportion of vaccinated individuals

from infection by virtue of being vaccinated.
Although the need for such studies seems self-evident, in the case of AIDS vaccine
studies practical and ethical concerns will make them extremely difficult to design. In the
initial studies,

it

excluded. This

is

who

become

are likely to

who are already

be certain that individuals

will be critically important to

infected with HIV, or

so in the ensuing several months, are

important, since one would not wish to put a potentially useful vaccine at

risk of being prematurely discarded because clinical manifestations of

HIV infection are

mistaken for untoward effects of the vaccine. In most vaccine studies in the past, these
concerns have caused investigators to move totally out of "at risk" groups for the very

since individuals at risk for

AIDS vaccine,
HIV infection have expressed a strong desire to be an integral

part of any vaccine studies,

from even the

early studies. Politically, this might prove to be difficult with respect to an

ation has caused

some

earliest

phase through the

finish.

This consider-

investigators to consider offering enrollment to HIV-seronegative

homosexual men who have been abstinent
nence during the period of the vaccine
In the placebo-controlled trial, in

for three

months and who

will guarantee absti-

trial.

which participants

will

be

at risk of

HIV

infection,

other ethical considerations are operative. Subjects must understand the study design in

terms of the placebo inclusion. They must be told that even

may

the vaccine
tion

and must be advised not

counseling

effective,

is

of the vaccine. This
tion

from

exposure
the virus,

is

it

to put

will

themselves

they receive active material,

be increasingly

will not

at risk

modes of infec-

of infection. To the extent that the

difficult to

demonstrate a protective effect

related to the fact that in order for a vaccine to demonstrate protec-

infection, vaccine recipients
rate. If trial
it

if

not work. Finally, participants must be counseled about

members

and control subjects need

to

have a significant

receive vaccine or placebo, and then are never exposed to

be possible

determine whether the vaccine

to

tional consideration relates to the

need

is

protective.

An addi-

to protect the confidentiality of study subjects.

This extends beyond usual concerns for such studies, because vaccinees will likely be
designated HIV-seropositive by the standard
that

widespread mandatory testing

is

HIV

serologic screening tests. To the extent

employed or appears

to

be on the horizon, potential

vaccine study participants will have a strong disincentive to take part in such vitally important

trials. It

has been proposed that vaccine

indicating participation in

HIV

from insurance companies and

vaccine
others.

trials in

These

trial

participants be given certificates

order to indemnify them from retribution

certificates

might or might not be useful

Table 2

Attributes of an Ideal
wide variety of HIV

AIDS Vaccine
and types

1

Effective against a

2.

Lacking immune-pathogenic or other untoward effects

3.

Effective against genital, blood-borne, or percutaneous exposure

4.

Inexpensive to prepare

5.

Easy to administer

6.

Stable upon storage
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strains

to

participants,

and would certainly expose them

group behavior

if

to a loss of confidentiality in

terms of risk

they were utilized.

A final consideration relates to the fact that successful completion of placebo-controlled vaccine studies in

one risk group

groups. In the case of sexual exposure,

will not assure protection to persons in other risk

it is

likely that less virus is presented than with

intravenous exposure with intravenous drug use and in transfusion-associated

HIV

trans-

mission. In addition, in that intravenous drug users and hemophiliacs not infected by

HIV

immuhealthy homo-

are frequently immunosuppressed by drugs and clotting factors, respectively, the

nologic response to a candidate vaccine might be less vigorous than that in
sexual men. Thus,
risk

it

will

group populations

uals,

be necessary to carry out vaccine

(for

trials in several different

example, homosexual men, intravenous drug users, heterosex-

and hemophiliacs).

The Ideal Vaccine
The

ideal

AIDS vaccine must satisfy

several requirements (table 2).

Development of such

modes of transmission of HIV, of the
and death, and of strain variability among

a vaccine requires a thorough understanding of the

mechanisms by which the virus causes illness
HIV isolates. The ideal vaccine must be safe; effective against a

variety of

HIV

isolates;

protective against either sexual or blood-borne exposure through needle sticks; inexpensive to produce; easy to administer;

and stable

in storage for

logical progress in basic vaccine design over the past

prolonged periods. Techno-

decade makes

it

likely that such a

vaccine will ultimately be produced. However, the impediments to development of such a

vaccine are substantial and are unlikely to be overcome in the near future. Although any
timetable must be viewed as highly speculative, a possible one

vaccine development process
description of the

syndrome

is

is

presented in table

already well under way, having begun with the

in 1981

.

As

3.

The

initial

outlined in the table, vaccine development should

be viewed as an orderly process that consists of a series of temporally overlapping but
discrete phases. At the present time, limited dose-finding studies have begun.
ies

These stud-

seek to determine whether vaccine preparations are safe to administer, and what dos-

ing schedule induces the most potent

has been established, larger,

more

immune response. Once an optimal dosing regimen

elaborate trials will be required to determine whether

the vaccine or vaccines actually prevent infection. Following this demonstration in several

be made available for commercial production. Although it is
make such predictions with precision, it seems unlikely to this au-

risk groups, the vaccine will

extremely difficult to
thor that

AIDS

vaccines will be widely available until at least 1994 or 1995.

Table 3

Timetable, Past and Potential, in the Development of an
1981

Clinical recognition of

1983-84

Identification of

1984-87

Delineation of

acquired immunodeficiency syndrome

HIV as etiologic agent for AIDS

components

of HIV recognized by host

1987-88

Phase human studies (safety and dose finding)

1989-93

Phase

immune response

I

II

and Phase

III

human

studies (controlled larger-scale clinical

with vaccine candidates)

1994-95

AIDS Vaccine

AIDS vaccine
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Conclusion
In

summary, much

is

now known about the immune response to HIV. This basic knowl-

edge has formed the framework for

initial

plans for developing

AIDS

vaccines.

AIDS

vaccine studies have progressed to the point that portions of the virus have been identified

which are capable of generating neutralizing

activity in animals.

To

vaccine preparation has been shown to prevent infection with live
lenge with the pathogenic virus.

Human

degree of protection,

if

not

no

following a chal-

studies are in the earliest phase at this writing,

but are both technically and ethically highly complex.
that offer a

date, however,

HIV

full

of this investigator that such a development

It is

likely that a vaccine or vaccines

protection, will be developed.
is at

144

least five years away. V|)

It is

the opinion

